You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 22, 2024

CLINICAL TRIALS PROFILE FOR NOVANTRONE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Novantrone

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002003 ↗ Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas Completed Lederle Laboratories Phase 2 1969-12-31 To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.
NCT00002259 ↗ Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma Completed Lederle Laboratories Phase 2 1969-12-31 To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.
NCT00002805 ↗ Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed National Cancer Institute (NCI) Phase 2 1997-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome in first relapse or who did not achieve first remission.
NCT00002805 ↗ Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed Children's Oncology Group Phase 2 1997-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome in first relapse or who did not achieve first remission.
NCT00002835 ↗ Combination Chemotherapy in Treating Patients With Lymphoma Completed National Cancer Institute (NCI) Phase 3 1995-10-30 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
NCT00002835 ↗ Combination Chemotherapy in Treating Patients With Lymphoma Completed M.D. Anderson Cancer Center Phase 3 1995-10-30 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
NCT00006114 ↗ Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy Unknown status GERCOR - Multidisciplinary Oncology Cooperative Group Phase 2 1999-05-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Novantrone

Condition Name

Condition Name for Novantrone
Intervention Trials
Recurrent Adult Acute Myeloid Leukemia 17
Acute Myeloid Leukemia 12
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities 10
Untreated Adult Acute Myeloid Leukemia 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Novantrone
Intervention Trials
Leukemia 43
Leukemia, Myeloid, Acute 40
Leukemia, Myeloid 39
Lymphoma 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Novantrone

Trials by Country

Trials by Country for Novantrone
Location Trials
United States 464
Canada 49
Australia 21
New Zealand 9
Puerto Rico 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Novantrone
Location Trials
California 20
Washington 18
Texas 17
New York 16
Ohio 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Novantrone

Clinical Trial Phase

Clinical Trial Phase for Novantrone
Clinical Trial Phase Trials
Phase 4 3
Phase 3 9
Phase 2 27
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Novantrone
Clinical Trial Phase Trials
Completed 40
Terminated 11
Active, not recruiting 8
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Novantrone

Sponsor Name

Sponsor Name for Novantrone
Sponsor Trials
National Cancer Institute (NCI) 31
Children's Oncology Group 6
Fred Hutchinson Cancer Research Center 6
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Novantrone
Sponsor Trials
Other 55
Industry 31
NIH 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.